FAM
CTKB icon

Fred Alger Management’s Cytek Biosciences CTKB Stock Holding History

Fred Alger Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-106,841
Closed -$982K – 526
2023
Q1 		$982K Buy
106,841
+18
+0% +$194 0.01% 387
2022
Q4 		$1.09M Buy
106,823
+432
+0.4% +$5.81K 0.01% 375
2022
Q3 		$1.57M Hold
106,391
– – 0.01% 355
2022
Q2 		$1.14M Sell
106,391
-2,123
-2% -$21.1K 0.01% 367
2022
Q1 		$1.17M Sell
108,514
-574
-0.5% -$7.75K ﹤0.01% 377
2021
Q4 		$1.78M Sell
109,088
-3,892
-3% -$81.5K ﹤0.01% 366
2021
Q3 		$2.42M Buy
+112,980
New +$2.66M 0.01% 340

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fred Alger Management's CTKB Position: Q2 2023 in Review

Fred Alger Management sold out of Cytek Biosciences (CTKB) in Q2 2023, closing a stake of 106,841 shares — an estimated $982K sold.

Fred Alger Management first reported a position in CTKB in Q3 2021 and held it in 7 quarters. The position peaked at $2.42M in Q3 2021. 101 funds tracked by Wall St. Rank hold CTKB as of Q2 2023.

  • Fred Alger Management reported no remaining Cytek Biosciences position as of Q2 2023 after selling out during the quarter.
  • Fred Alger Management sold 106,841 Cytek Biosciences shares in Q2 2023, an estimated $982K.
  • Fred Alger Management first reported a position in Cytek Biosciences in Q3 2021 and held it in 7 quarters.
  • Fred Alger Management's Cytek Biosciences position peaked at $2.42M in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2023.

Based on Fred Alger Management's 13F filing for Q2 2023, filed 14 Aug 2023.